|
| General Information |
| Business: |
We are a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. We are using our proprietary RNA interference (RNAi) technology platform, which we believe improves on existing RNAi technologies, to build a broad pipeline in these therapeutic areas. We intend to discover, develop and commercialize novel therapeutics either on our own or in collaboration with pharmaceutical partners. In indications such as rare diseases in which a small sales force will suffice, we expect to retain substantially all commercial rights in key markets. In oncology and other more prevalent disease areas, we intend to partner our product candidates while seeking to retain significant portions of the commercial rights in North America. We have partnered two of our oncology development programs with the global pharmaceutical company Kyowa Hakko Kirin Co., Ltd. (KHK). We are eligible to receive royalties on worldwide net sales for these product candidates. We have an option to co-promote any product candidate targeting the oncogene KRAS, the more advanced of these two programs, in the U.S. for an equal share of the profits from U.S. net sales. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
24 |
Founded: |
2006 |
|
| Contact Information |
| Address: |
480 Arsenal Street, Building 1, Suite 120, Watertown, MA 02472 , US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 6.3 mil (last 12 months) |
|
| Net Income: |
$ -10.3 mil (last 12 months) |
|
| IPO Profile |
|
|
|
|
